Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Aztiq Pharma Partners S.a r.l. - 17 Dec 2025 SCHEDULE 13D/A Report for Alvotech Ordinary Shares, nominal value of $0.01 per share (ALVO)
- Filing manager
- Aztiq Pharma Partners S.a r.l.
- Reporting owner
- Aztiq Pharma Partners S.a r.l.
- Beneficially owned shares
- 103,849,420 shares
- Large-stake signal
-
Ownership
33%Beneficial ownership of this reported class.
Shares
103,849,420 sharesShares beneficially owned as disclosed.
Event date
17 Dec 2025Date tied to the ownership event or amendment.
Accepted by SEC
12 Mar 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 33%
- Symbol
- ALVO
- Shares outstanding
- 311,860,120 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 12 Mar 2026, 16:09:00 UTC
- Event date
- 17 Dec 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Aztiq Pharma Partners S.a r.l. disclosed 33% ownership in Alvotech Ordinary Shares, nominal value of $0.01 per share (ALVO) on 17 Dec 2025.
Key facts
- Aztiq Pharma Partners S.a r.l. filed SCHEDULE 13D/A for Alvotech Ordinary Shares, nominal value of $0.01 per share (ALVO).
- Disclosed ownership: 33%.
- Date of event: 17 Dec 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Mar 2026, 16:09.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (5)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Aztiq Pharma Partners S.a r.l. | 33% | 103,849,420 | 0 | 103,849,420 | /s/ David Olafsson | By David Olafsson, Manager | 0001936288 |
| Aztiq Fund I SCSp | 33% | 103,849,420 | 0 | 103,849,420 | /s/ David Olafsson | By Floki GP S.a r.l., its general partner, By David Olafsson, Manager | |
| Floki GP S.a r.l. | 33% | 103,849,420 | 0 | 103,849,420 | /s/ David Olafsson | By David Olafsson, Manager | |
| ATP ehf. | 1% | 3,003,290 | 0 | 3,003,290 | /s/ David Olafsson | By David Olafsson, Director | |
| ATP Holdings ehf. | 1% | 3,020,861 | 17,571 | 3,003,290 | /s/ David Olafsson | By David Olafsson, Director |
CIK / CUSIP context first